Literature DB >> 17981503

Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.

Daniel S Straus1, Christopher K Glass.   

Abstract

The peroxisome proliferator-activated receptors (PPARalpha, -gamma, and -beta/delta) are nuclear receptors with distinct patterns of expression in many cell types both within and outside the immune system. PPAR ligands have anti-inflammatory activity in a variety of mouse models for acute and chronic inflammation. In macrophages, PPARgamma ligands repress expression of a subset of Toll-like receptor (TLR) target genes by a molecular mechanism termed ligand-dependent transrepression. In chronic inflammation, ligand-bound PPARalpha represses production of IFNgamma and IL-17 by CD4(+) T cells, and PPARgamma ligands modulate dendritic cell function to elicit the development of anergic CD4(+) T cells. PPAR ligands also repress expression of cell adhesion molecules on endothelial cells and the secretion of chemokines by epithelial and other cells, decreasing the recruitment of leukocytes to the site of inflammation. The anti-inflammatory activity of PPAR ligands in mouse models suggests their possible use for treating human inflammatory and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981503     DOI: 10.1016/j.it.2007.09.003

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  207 in total

1.  PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage.

Authors:  Maria Paola Simula; Renato Cannizzaro; Vincenzo Canzonieri; Alessandro Pavan; Stefania Maiero; Giuseppe Toffoli; Valli De Re
Journal:  Mol Med       Date:  2010-03-03       Impact factor: 6.354

2.  A subclass of acylated anti-inflammatory mediators usurp Toll-like receptor 2 to inhibit neutrophil recruitment through peroxisome proliferator-activated receptor gamma.

Authors:  Elizabeth M Long; Alexander C Klimowicz; Heitor A Paula-Neto; Brandie Millen; Donna-Marie McCafferty; Paul Kubes; Stephen M Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

3.  NKG2D receptor regulates human effector T-cell cytokine production.

Authors:  Amorette Barber; Charles L Sentman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

4.  PPARs and lipid ligands in inflammation and metabolism.

Authors:  Gregory S Harmon; Michael T Lam; Christopher K Glass
Journal:  Chem Rev       Date:  2011-10-12       Impact factor: 60.622

5.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

6.  Inhibition of TLR4-induced IκB kinase activity by the RON receptor tyrosine kinase and its ligand, macrophage-stimulating protein.

Authors:  Manujendra Ray; Shan Yu; Daniel R Sharda; Caleph B Wilson; QingPing Liu; Naveen Kaushal; K Sandeep Prabhu; Pamela A Hankey
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

Review 7.  Cytokine signaling modulates blood-brain barrier function.

Authors:  Weihong Pan; Kirsten P Stone; Hung Hsuchou; Vamshi K Manda; Yan Zhang; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

Review 8.  Macrophage polarization: the link between inflammation and related diseases.

Authors:  Samina Bashir; Yadhu Sharma; Asif Elahi; Farah Khan
Journal:  Inflamm Res       Date:  2016-01       Impact factor: 4.575

9.  PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.

Authors:  Danielle N Lyons; Liping Zhang; Robert J Danaher; Craig S Miller; Karin N Westlund
Journal:  Clin J Pain       Date:  2017-12       Impact factor: 3.442

10.  Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease.

Authors:  Ruby F Fernandez-Boyanapalli; S Courtney Frasch; Stacey M Thomas; Kenneth C Malcolm; Michael Nicks; Ronald J Harbeck; Claudia V Jakubzick; Raphael Nemenoff; Peter M Henson; Steven M Holland; Donna L Bratton
Journal:  J Allergy Clin Immunol       Date:  2014-12-10       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.